Alkermes plc has received significant regulatory recognition for its investigational sleep disorder therapy alixorexton, with health authorities in both the United States and Europe granting orphan drug designations that could accelerate the drug’s development and commercialization for rare neurological conditions.
The company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to alixorexton for the treatment of idiopathic hypersomnia (IH), while the European Commission has awarded orphan designation for the treatment of narcolepsy. The designations represent an important milestone for Alkermes as it advances the oral therapy through late-stage clinical development.
Alixorexton is a selective orexin 2 receptor (OX2R) agonist being developed as a potential treatment for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia. These rare neurological disorders are characterized by excessive daytime sleepiness and can significantly affect patients’ quality of life, daily functioning, and overall health.
According to Alkermes, the new regulatory designations underscore the continuing need for innovative treatment options in these underserved patient populations. While existing therapies can help manage symptoms, many patients continue to experience substantial disease burden, creating demand for new approaches that target the underlying biological mechanisms involved in sleep-wake regulation.
Craig Hopkinson, Chief Medical Officer and Executive Vice President of Research and Development at Alkermes, said the orphan drug designations highlight the potential of alixorexton to address significant unmet medical needs in both narcolepsy and idiopathic hypersomnia. He noted that recent Phase 2 clinical trial results in narcolepsy type 1 and type 2 patients have demonstrated encouraging outcomes, supporting the therapy’s potential as a differentiated treatment option.
Orphan drug designation is intended to encourage the development of treatments for rare diseases. In the United States, the designation provides several incentives to drug developers, including tax credits for qualified clinical testing, exemptions from certain FDA application fees, and seven years of market exclusivity if the therapy ultimately receives approval. In the European Union, orphan designation may provide regulatory assistance, reduced fees, and up to ten years of market exclusivity following approval.
The latest recognition builds on previous regulatory support for alixorexton. The FDA had earlier granted Breakthrough Therapy designation to the drug for the treatment of narcolepsy type 1, reflecting its potential to offer substantial improvement over existing therapies.
Alkermes is currently evaluating alixorexton in a comprehensive clinical development program. The therapy is being studied in the Phase 3 Brilliance Studies involving adults with narcolepsy type 1 and type 2, while a separate Phase 2 trial, known as Vibrance-3, is assessing its safety and efficacy in adults with idiopathic hypersomnia.
The company expects to continue advancing enrollment in the Brilliance program while working toward completion of the Vibrance-3 study later this year. Positive outcomes from these trials could position alixorexton as a novel treatment option for patients living with rare sleep disorders, potentially expanding therapeutic choices in a field where innovation has remained relatively limited.
With dual orphan drug designations now secured in major markets, Alkermes has strengthened the regulatory foundation for alixorexton as it moves closer to potential commercialization and broader patient access.